CSPC PHARMA (01093): Rigefinib tablets obtained drug registration approval.

CSPC PHARMA (01093) announced that the company's developed Regorafenib tablets (40mg) have obtained the drug registration approval letter issued by the National Medical Products Administration of the People's Republic of China, and are considered to have passed the evaluation of generic drug quality and efficacy consistency. Regorafenib is a small molecule oral multikinase inhibitor, indicated for the treatment of patients with metastatic colorectal cancer (mCRC) who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as well as for patients who have previously received or are not suitable for anti-VEGF therapy, anti-EGFR therapy (RAS wild type). It is also indicated for the treatment of locally advanced, unresectable or metastatic gastrointestinal stromal tumors (GIST) previously treated with imatinib mesylate and sunitinib malate, and for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib. The approval of this product will further enrich the company's product line in the field of anti-tumor therapy.